Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasms 4 Recurrence 3 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Endometrial Neoplasms 2 Breast Diseases 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Spinal Cord Neoplasms 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Neurofibromatosis 1 1 Neoplasms, Squamous Cell 1 Multiple Myeloma 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Liposarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 HR+/HER2- Breast Cancer 1 Glioma 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Brain Diseases 1

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × abemaciclib × 30 days × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡